ZURA BIO LIMITED Proceeds from Issuance of Private Placement
ZURA BIO LIMITED (ZURA) reported Proceeds from Issuance of Private Placement of $123.37 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2026-08-11
- ZURA BIO LIMITED proceeds from issuance of private placement for the quarter ending 2026-06-30 was -$123.75M.
- ZURA BIO LIMITED proceeds from issuance of private placement for the quarter ending 2026-03-31 was $123.88M.
- ZURA BIO LIMITED proceeds from issuance of private placement for the quarter ending 2025-06-30 was $0.00.
- ZURA BIO LIMITED proceeds from issuance of private placement for the quarter ending 2025-03-31 was $0.00.
- ZURA BIO LIMITED proceeds from issuance of private placement for fiscal 2023 was $59.72M.
| Period end | Proceeds from Issuance of Private Placement 1 month | Proceeds from Issuance of Private Placement 1 month as first filed | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 7 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 10 month | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$123.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $123.37K 10-Q · filed 2026-08-11 | ||||||
| 2026-03-31 | $123.88M 10-Q · filed 2026-05-07 | |||||||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | ||||||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | |||||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$4.12M derived: sum of 2 quarters · filed 2024-03-28 | $59.72M 10-K · filed 2024-03-28 | |||||
| 2023-09-30 | -$4.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $59.72M 10-Q · filed 2023-11-13 | ||||||
| 2023-06-30 | $63.85M 10-Q · filed 2023-08-14 | |||||||
| 2023-04-30 | $75.80M 10-K · filed 2024-03-28 | $79.90M 10-Q · filed 2023-08-14 | ||||||
| 2021-12-31 | $5.91M 10-K · filed 2023-03-28 | |||||||
| 2021-09-30 | $5.91M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |